Lectenz Bio receives NIH NIGMS SBIR Phase II
The National Institutes of Health (NIH) National Institute of General Medical Sciences (NIGMS) awards Lectenz Bio an SBIR Phase II to further...
Read moreThe National Institutes of Health (NIH) National Institute of General Medical Sciences (NIGMS) awards Lectenz Bio an SBIR Phase II to further...
Read moreWe are excited to have our SiaFind™ products used in the Derda lab at the University of Alberta. Read the paper, “Chemoenzymatic...
Read moreThe National Institute of Health (NIH) Office of Research Infrastructure Programs (ORIP) awards Lectenz Bio an SBIR Fast-Track to develop N-glycan...
Read moreLectenz Bio has recently signed a distribution agreement with ZAGENO, a European life science distributor. This agreement will allow ZAGENO to...
Read moreLectenz Bio’s paper, “Simplifying the detection and monitoring of protein glycosylation during in vitro glycoengineering,” has...
Read moreCedarlane is now distributing Lectenz Bio products for Canadian customers. We are excited to have Cedarlane listing our catalog and look forward...
Read moreLectenz Bio has recently signed a distribution agreement with MBL Beijing Biotech Co., Ltd., a Chinese life science distributor. This agreement...
Read moreLectenz Bio has recently signed a distribution agreement with Scientist.com, a U.S. life science distributor. This agreement will allow...
Read moreLectenz Bio was excited to have CEO Lori Yang and VP of R&D Sean Wu present at the Common Fund GlycoScience Program!
Read moreLectenz Bio was proud to be a sponsor of the 2022 Rare Disease Day Symposium & CDG/NGLY1 Family Conference! It’s always exciting to see...
Read moreLectenz Bio has recently signed a distribution agreement with Krishgen Biosystems, an Indian life science distributor. This agreement will allow...
Read moreLectenz Bio has recently signed a distribution agreement with Advion Interchim, a French life science distributor. This agreement will allow...
Read more